What is the purpose of the study?
We are conducting a research study to evaluate the use of cannabidiol for people with bipolar depression. The usual treatment for bipolar depression is pharmacotherapy with mood stabilizers such as lithium, or atypical antipsychotics such as quetiapine. However, many people do not experience sufficient improvement with these treatments. The purpose of this study is to find out the potential benefits of cannabidiol on bipolar depression.
Who is needed?
The study is recruiting individuals (19-70 years old) with bipolar I or bipolar II depression who have used a first-line treatment for bipolar I depression (i.e. lithium, quetiapine, lamotrigine, or lurasidone), or at least one first or second-line treatment for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy), but had not seen adequate improvement in symptoms.
- Age range: 19-70
- Gender: All
- Ethnicity: All
- Have been diagnosed with bipolar depression
- Have used a first-line treatment for bipolar I depression (i.e. lithium, quetiapine, lamotrigine, or lurasidone), or at least one first or second-line treatment for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy) but had not seen adequate improvement in symptoms.
Study Details:
Type of Study: Clinical Trial
Number of contacts: 5
Time Period: 10 weeks
Treatment offered: Yes
Compensation offered: Yes
Study End Date: June 3, 2026
REB number:081/2023
Full Study Title: Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind, Placebo Controlled Trial